These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15352988)

  • 41. Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse.
    Serrano J; Román J; Herrera C; Castillejo JA; Navarro JA; Reina ML; González MG; Rodriguez MC; Pascual A; Sánchez J; Torres A
    Bone Marrow Transplant; 1999 Mar; 23(5):475-82. PubMed ID: 10100562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens.
    Michallet AS; Fürst S; Le QH; Dubois V; Praire A; Nicolini F; Thomas X; Rafii H; Gebuhrer L; Michallet M
    Br J Haematol; 2005 Mar; 128(5):676-89. PubMed ID: 15725090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody and pre- plus post-transplant prednisone treatments support T cell-depleted stem cell engraftment without drug-induced morbidity.
    D'Costa S; Hurwitz JL
    Bone Marrow Transplant; 2002 Apr; 29(7):553-6. PubMed ID: 11979302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
    Fowler DH; Odom J; Steinberg SM; Chow CK; Foley J; Kogan Y; Hou J; Gea-Banacloche J; Sportes C; Pavletic S; Leitman S; Read EJ; Carter C; Kolstad A; Fox R; Beatty GL; Vonderheide RH; Levine BL; June CH; Gress RE; Bishop MR
    Biol Blood Marrow Transplant; 2006 Nov; 12(11):1150-60. PubMed ID: 17085308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.
    Salit RB; Fowler DH; Dean RM; Pavletic SZ; Hakim FT; Steinberg SM; Hardy NT; Sportes C; Gress RE; Bishop MR
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1509-13. PubMed ID: 23948062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T-cell depletion does not necessarily compromise donor stem cell engraftment in patients receiving reduced-intensity conditioning regimens.
    Craddock C; Grigg AP
    Bone Marrow Transplant; 2003 Jun; 31(12):1177; author reply 1179. PubMed ID: 12796800
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.
    Michálek J; Collins RH; Vitetta ES
    Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host.
    Hummel S; Wilms D; Vitacolonna M; Zöller M
    J Leukoc Biol; 2002 Nov; 72(5):898-912. PubMed ID: 12429711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
    Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Mohty M; Bagattini S; Chabannon C; Faucher C; Bardou VJ; Bilger K; Vey N; Gaugler B; Stoppa AM; Coso D; Ladaique P; Olive D; Viens P; Blaise D
    Exp Hematol; 2004 Nov; 32(11):1097-102. PubMed ID: 15539088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.
    Alyea EP; Canning C; Neuberg D; Daley H; Houde H; Giralt S; Champlin R; Atkinson K; Soiffer RJ
    Bone Marrow Transplant; 2004 Jul; 34(2):123-8. PubMed ID: 15133487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases.
    Willasch A; Hoelle W; Kreyenberg H; Niethammer D; Handgretinger R; Lang P; Beck JF; Klingebiel T; Bader P
    Haematologica; 2006 Jun; 91(6):788-94. PubMed ID: 16769581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.